+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Stelara"

Interleukin Inhibitors Market Report 2025 - Product Thumbnail Image

Interleukin Inhibitors Market Report 2025

  • Report
  • April 2025
  • 250 Pages
  • Global
From
From
From
From
From
From
From
Plaque Psoriasis - Pipeline Insight, 2024 - Product Thumbnail Image

Plaque Psoriasis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 240 Pages
  • Global
From
STELARA Market Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

STELARA Market Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • January 2023
  • 30 Pages
  • Global
From
From
From
From
From
Loading Indicator

Stelara is a biologic drug used to treat immune disorders such as psoriasis, Crohn's disease, and ulcerative colitis. It is a monoclonal antibody that works by blocking the action of two proteins, interleukin 12 and interleukin 23, which are involved in the body's inflammatory response. Stelara is administered as an injection or infusion, and is typically used in combination with other medications. Stelara is a relatively new drug, having been approved by the US Food and Drug Administration in 2009. It has become a popular treatment option for immune disorders due to its effectiveness and relatively low side effects. The Stelara market is highly competitive, with several major pharmaceutical companies offering their own versions of the drug. These include Johnson & Johnson, AbbVie, Merck, and Pfizer. Other companies, such as Amgen and Biogen, are also developing their own versions of the drug. Show Less Read more